GSK plc (LON:GSK) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of GSK plc (LON:GSK - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is GBX 1,805.83 ($23.34).

A number of research analysts recently issued reports on GSK shares. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank reduced their price target on GSK from GBX 1,820 ($23.52) to GBX 1,600 ($20.68) and set a "buy" rating for the company in a research report on Friday, November 29th.

GSK Stock Up 2.2 %

GSK traded up GBX 33.50 ($0.43) during trading on Wednesday, reaching GBX 1,534 ($19.83). The company had a trading volume of 9,518,768 shares, compared to its average volume of 20,720,889. The business's fifty day moving average price is GBX 1,407.87 and its 200 day moving average price is GBX 1,445.55. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. GSK has a 12 month low of GBX 1,282.50 ($16.58) and a 12 month high of GBX 1,823.50 ($23.57). The company has a market cap of £62.25 billion, a P/E ratio of 24.78, a PEG ratio of 1.24 and a beta of 0.31.

Remove Ads

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling

In related news, insider Jonathan Symonds acquired 1,500 shares of GSK stock in a transaction on Friday, December 20th. The stock was purchased at an average cost of GBX 1,315 ($17.00) per share, with a total value of £19,725 ($25,494.38). Also, insider Emma Walmsley sold 38,459 shares of the business's stock in a transaction that occurred on Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($18.33), for a total value of £545,348.62 ($704,857.98). 1.61% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.